0.00Open0.03Pre Close0 Volume0 Open Interest5.00Strike Price0.00Turnover3737.70%IV49.49%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier-7DDays to Expiry0.03Extrinsic Value100Contract SizeAmericanOptions Type-0.0195Delta0.0128Gamma328.00Leverage Ratio-2.2964Theta0.0000Rho-6.39Eff Leverage0.0000Vega
Kyverna Therapeutics Stock Discussion
Kyverna's KYV-101 Receives U.S. FDA RMAT Designation for KYV-101 in the Treatment of Patients With Refractory Stiff-Person Syndrome
Kyverna Therapeutics (KYTX) has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for KYV-101, its autologous CD19 CAR T-cell therapy, in treating refractory stiff-person syndrome. This designation, based on positive clinical outcomes in Germany, allows Kyverna to receive expert guidance on efficient ...
No comment yet